Association of clinicopathological features with E-cadherin (CDH1) gene-160 C>A promoter polymorphism in Turkish colorectal cancer patients

Cdh1 Gene ◽

Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients

Clinical & Experimental Metastasis ◽

10.1023/b:clin.0000017204.38807.22 ◽

2004 ◽

Vol 21 (1) ◽

pp. 75-78 ◽

Cited By ~ 21

Author(s):

C. Wilmanns ◽

J. Grossmann ◽

S. Steinhauer ◽

G. Manthey ◽

B. Weinhold ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Tumour Progression ◽

E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer

International Journal of Colorectal Disease ◽

10.1007/s00384-011-1320-7 ◽

2011 ◽

Vol 27 (2) ◽

pp. 151-158 ◽

Cited By ~ 4

Author(s):

Yadong Wang ◽

Haiyan Yang ◽

Li Li ◽

Haiyu Wang ◽

Congke Zhang ◽

...

Keyword(s):

Colorectal Cancer ◽

Gene Promoter ◽

Promoter Polymorphism ◽

Cdh1 Gene ◽

Gene Promoter Polymorphism ◽

Association between elevated microsatellite alterations at selected tetranucleotides (EMAST) and clinicopathological features of colorectal cancer patients: a molecular trait of proximal colon cancer in the elderly?

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.10.202 ◽

2019 ◽

Vol 45 (2) ◽

pp. e51-e52

Author(s):

M. Watson ◽

A. Kanani ◽

D. Lea ◽

R. Khajavi ◽

J.A. Søreide ◽

...

Keyword(s):

Colorectal Cancer ◽

Colon Cancer ◽

Cancer Patients ◽

The Elderly ◽

Proximal Colon ◽

Contribution of the MLH1 -93G>A Promoter Polymorphism in Modulating Susceptibility Risk in Malaysian Colorectal Cancer Patients

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2013.14.2.619 ◽

2013 ◽

Vol 14 (2) ◽

pp. 619-624 ◽

Cited By ~ 6

Author(s):

Zahary Mohd Nizam ◽

Ahmad Aizat Abdul Aziz ◽

Gurjeet Kaur ◽

Muhammad Radzi Abu Hassan ◽

Ahmad Shanwani Mohd Sidek ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Promoter Polymorphism ◽

Investigation of hTERT Expression Level and its Relation with Clinicopathological Features and Resistance to Chemotherapy in Colorectal Cancer Patients

Journal of Molecular Biomarkers & Diagnosis ◽

10.4172/2155-9929.1000176 ◽

2014 ◽

Vol 05 (03) ◽

Author(s):

Rezvan Mirzaee

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Expression Level ◽

Htert Expression ◽

Resistance To Chemotherapy

Cyclooxygenase (COX)-1, Cyclooxygenase (COX)-2 and E-cadherin Expression in Colorectal Cancer Patients with Hepatic Metastasis

Journal of the Korean Surgical Society ◽

10.4174/jkss.2010.78.3.177 ◽

2010 ◽

Vol 78 (3) ◽

pp. 177

Author(s):

Sun Hyung Joo ◽

Bum Soo Kim ◽

Sung Il Choi ◽

Jeong Yoon Song ◽

Kil Yeon Lee ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Hepatic Metastasis ◽

Cox 2 ◽

Cox 1 ◽

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients

Annals of Oncology ◽

10.1093/annonc/mdq771 ◽

2011 ◽

Vol 22 (11) ◽

pp. 2431-2439 ◽

Cited By ~ 19

Author(s):

T. Winder ◽

P. Bohanes ◽

W. Zhang ◽

D. Yang ◽

D.G. Power ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Outcome ◽

Cancer Patients ◽

Promoter Polymorphism ◽

Potential Predictor ◽

Grp78 Promoter ◽

Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients

Diagnostic Pathology ◽

10.1186/1746-1596-8-99 ◽

2013 ◽

Vol 8 (1) ◽

Cited By ~ 27

Author(s):

Sang-Jeon Lee ◽

Song Yi Choi ◽

Wun-Jae Kim ◽

Meiying Ji ◽

Taek-Gu Lee ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Disease Free Survival ◽

Aberrant Expression ◽

Free Survival ◽

Disease Free ◽

Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients

Pathology & Oncology Research ◽

10.1007/s12253-017-0195-5 ◽

2017 ◽

Vol 24 (1) ◽

pp. 45-57 ◽

Cited By ~ 5

Author(s):

Mei Jin ◽

Zi-Wen Long ◽

Jing Yang ◽

Xiang Lin

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Genetic Mutations ◽

Cox 2 ◽

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting

Translational Oncology ◽

10.1016/j.tranon.2015.11.002 ◽

2015 ◽

Vol 8 (6) ◽

pp. 474-479 ◽

Cited By ~ 11

Author(s):

Chien-Yu Lu ◽

Ching-Wen Huang ◽

I-Chen Wu ◽

Hsiang-Lin Tsai ◽

Cheng-Jen Ma ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Dose Escalation ◽

Clinical Implication ◽

Promoter Polymorphism ◽

First Line ◽

Line Setting ◽

Irinotecan Dose